JNK inhibitor efficiently suppresses RhoA activation-promoted wound closure after activin B treatment.

<p>Forty three mice were randomly assigned to three groups: Act B+EFGP+SP600125 (n = 16), Act B+RhoAL63+SP600125 (n = 16) and RhoAL63+SP600125 (n = 11). Mice were infected with GFP or RhoAL63 after wound creation. Thirty minutes after lentivirus infection, 0.2 ml SP600125 (5 µM) was injected on the same area. After another 30 min, 0.2 ml of activin B (10 ng/ml) was administered. Mice were received such SP600125 and activin B treatment three times a day. (A) SP600125 suppressed wound closure in mice treated with activin B. (B) Wound closure rate was calculated 3 and 5 days after treatment. (C) BrdU-positive cells were visualized on both epithelium (i) and hair follicle (ii). Pictures were taken at 100× magnification, and corresponding magnification pictures were taken at 400× magnification. Scale bars: 100 µm. Data were quantified in three independent experiments and the number of BrdU-positive cells per mm² in epithelium (D) and hair follicle (E) was presented. *<i>P</i><0.05 compared with PBS control. **<i>P</i><0.05 compared with PBS, Act B+RhoAL63+SP600125, RhoAL63+SP600125 and Act B+EGFP+SP600125 groups, ***<i>P</i><0.05 compared with PBS, Act B, Act B+RhoAL63+SP600125, RhoAL63+SP600125 and Act B+EGFP+SP600125 groups.